See more : Provident Financial Services, Inc. (PFS) Income Statement Analysis – Financial Results
Complete financial analysis of Quince Therapeutics, Inc. (QNCX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quince Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- EZGO Technologies Ltd. (EZGO) Income Statement Analysis – Financial Results
- Excelsior Mining Corp. (MIN.TO) Income Statement Analysis – Financial Results
- Dayang Enterprise Holdings Bhd (5141.KL) Income Statement Analysis – Financial Results
- Huili Resources (Group) Limited (1303.HK) Income Statement Analysis – Financial Results
- Stemcell Holdings, Inc. (STMM) Income Statement Analysis – Financial Results
Quince Therapeutics, Inc. (QNCX)
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 322.00K | 175.00K | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| Gross Profit | -322.00K | -175.00K | -344.00K | -332.00K | -188.00K | -51.00K | -45.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.45M | 25.18M | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 17.70M | 26.01M | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.70M | 26.01M | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 7.48M | -997.00K | -247.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 34.62M | 51.19M | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 34.62M | 51.19M | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 3.48M | 1.07M | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 568.00K | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 322.00K | 175.00K | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -31.26M | -52.02M | -89.97M | -78.56M | -38.98M | -12.07M | -10.33M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -34.62M | -52.02M | -90.32M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.04M | 71.00K | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -31.58M | -51.94M | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -197.00K | -284.00K | -620.00K | 2.17M | -188.00K | 357.00K | 1.87M |
| Net Income | -31.39M | -51.66M | -89.33M | -76.85M | -36.79M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.84 | -1.54 | -3.01 | -2.63 | -1.93 | -0.58 | -0.57 |
| EPS Diluted | -0.84 | -1.54 | -3.01 | -2.63 | -1.93 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 21.55M | 21.55M |
Cortexyme Stock Sinks After FDA Puts Application on Hold
Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND
Why Cortexyme Stock Imploded in 2021
3 Most-Shorted Stocks at 52-Week Lows to Buy
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
5 Short Squeeze Candidates To Watch: Pioneer Power, NuZee Remain At The Top, Grab Rejoins The Leaderboard
Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?
Cortexyme: A Challenging Path Forward
Why Are Cortexyme Shares Falling Today?
Source: https://incomestatements.info
Category: Stock Reports